CHARACTERISTIC OVERVIEW OF DRUG RESISTANT TUBERCULOSIS IN NORTH SUMATERA PROVINCE 2024
Keywords:
Drug Resistant Tuberculosis, Characteristic TBC, TuberculosisAbstract
Indonesia is the second country with high insidence Tuberculosis (TBC) and Drug Resistant Tuberculosis (DR TBC) after India. Proggramatic Management Drug Resistant Tuberculosis (PMDT) is a program for MDR TBC. This research aims to investigate the characteristics of DR TBC Patients in North Sumatera Province in 2024. This research using retrospective cross sectional method with descriptive analytic. This research uses secondary data from Tuberkulosis Information System (SITB) covering the period from January – december 2024. The population are DR TBC patients with Resistant Rifampisin diagnose using Gen Expert or BD MAX amount 676 people as sampel. The result showed that majority of respondents were 69% male, age 19 -59 years in 80% with unemployed status 66%. Diagnose confirmation using Gen Expert 99,3% which 63% Resistant Rifampisin confirmed using Gen Expert (99,3%) from primary suspected criteria. Baseline diagnostic using drug resistant sensitivity test 61% and XDR test 28% with BPALM regiment (50%). Conclusion of this study that it is importance to enhance awarness and early detection or DR-TBC cases in productive age, improve access to DR-TBC treatment to enable prompt initiation, develop social and economic support strategies for DR-TBC patients, and improve the quality of data and reporting.
Downloads
References
1] Aini, Z.M. and Rufia, N.M. (2019) ‘Research Purpose: This study is to explain the characteristics of patients with MDR TB in Southeast Sulawesi in 2014-2017’, Medula: Scientific Journal of Medical Faculty of Halu Oleo University, pp. 2014–2017.
2] Albaihaqi, N.A., Burhanuddin and Latuconsina, V.Z. (2020) ‘Karakteristik Pasien Tuberkulosis Paru dengan Multidrug-Resistant (TB MDR) di RSUD Dr. Haulussy Ambon Tahun 2014 - 2018’, Pameri [Preprint].
3] Andayani, S. (2020) ‘Prediksi Kejadian Penyakit Tuberkulosis Paru Berdasarkan Jenis Kelamin’, Jurnal Keperawatn Muhammadiyah Bengkulu, 8(2), pp. 135–140. Available at: https://doi.org/10.36085/jkmu.v8i2.1063.
4] Arifah, N., Sukartini, T. and Harmayetty, H. (2019) ‘Karakteristik Pasien Multidrug Resistant Tuberculosis (MDR-TB) di RSUD Makassar’, Jurnal Penelitian Kesehatan ‘SUARA FORIKES’ (Journal of Health Research ‘Forikes Voice’), 10(4), p. 253. Available at: https://doi.org/10.33846/sf10401.
5] Azwar, G.A., Indah Noviana, D. and Hendriyono, F.X. (2017) ‘Karakteristik Penderita Tuberkulosis Paru dengan Multidrug-Resistant Tuberkulosis (MDR-TB) di RSUD Ulin Banjarmasin’, Berkala Kedokteran [Preprint].
6] Damayanti, L., Widada, W. and Adi, G.S. (2022) ‘Status Pengobatan Berhubungan dengan kejadian Tuberkulosis Resistan Obat pada Usia Produktif’, Profesional Health Jpurnal, 3.
7] Fauziyantini, Ta.N. (2025) ‘Manajemen Regimen Terapi pada Pasien Tuberculosis Multidrug Resistan (TB - MDR) di Indonesia’,
8] Bandung Conference Series: Pharmacy, pp. 145–154.
9] Kementerian Kesehatan RI (2023) Laporan Program Penanggulangan Tuberkulosis Tahun 2023.
10] Kementerian Kesehatan RI (2021) Laporan Program Penanggulangan Tuberkulosis Tahun 2021 Kementerian Kesehatan Republik Indonesia Tahun 2022.
11] Kementerian Kesehatan RI (2023a) ‘1. Buku Operasional Pengobatan TBC RO dengan BPAL BPALM’.
12] Kementerian Kesehatan RI (2023b) Petunjuk Teknis Pemeriksaan Line Probe Assay (LPA) Lini Satu dan Dua.
13] Kementerian Kesehatan RI (2024) Petunjuk Teknis Penatalaksanaan Tuberkulosis Resistan Obat di Indonesia.
14] Kementerian Kesehatan RI. Direktorat Jenderal Pencegahan dan Pengendalian Penyakit (2020) Petunjuk Teknis Penatalaksanaan Tuberkulosis Resistan Obat di Indonesia.
15] Kusumandari, V.P., Sunarti and Nawangsari, D. (2023) ‘Pengaruh Riwayat Pengobatan Pasien TB Terhadap Kejadian TB MDR di RSUD Prof. DR Margono Soekarjo’, Pharmacy Genius, pp. 176–188.
16] Manggasa, D.D. and Suharto, D.N. (2022) ‘Riwayat Pengobatan dan Komorbid Diabetes Mellitus Berhubungan dengan Kejadian Tuberkulosis Resistan Obat’, Poltekia: Jurnal Ilmu kesehatan [Preprint].
17] Munir, S.M. et al. (2010) Pengamatan Pasien Tuberkulosis Paru dengan Multidrug Resistant (TB-MDR) di Poliklinik Paru RSUP Persahabatan, J Respir Indo.
18] Nugrahaeni, D.K. (2015) ‘Analisis Penyebab Resistansi Obat Anti Tuberkulosis’, Jurnal Kesehatan Masyarakat, 11(1), p. 8. Available at: https://doi.org/10.15294/kemas.v11i1.3341.
19] Nurdin, N. (2020) ‘Analysis of Individual Risk Factors of Tuberculosis Multidrug-Resistant (MDR TB) in South Sumatra Province’, Jurnak Kesehatan Komunitas [Preprint].
20] Perdana Rizal, V., Rustam, E. and Anggrainy, F. (2021) Karakteristik Pasien Multidrug Resistant Tuberculosis yang Dirawat di Bangsal Paru RSUP Dr. M. Djamil Padang Periode 2018-2020, Jurnal Farmasi Higea.
21] Pratama, I.G.B. et al. (2021) ‘Karakteristik Pasien Tuberkulosis Paru dengan Multidrug Resistance di RSUP Sanglah, Bali’, Jurnal Medika Udayana, 10.
22] Raka, G. et al. (2024) ‘Karakteristik pasien tuberkulosis paru dengan multidrug-resistance di Rumah Sakit Pusat Dr. Kariadi Semarang tahun 2021- 2022’, Fakultas Kedokteran Universitas Udayana | Medicina, 55(1), pp. 26–29. Available at: https://doi.org/10.15562/medicina.v55i1.1292.
23] Rinawati, S.A.W. (2021) ‘Indeks Massa Tubuh (IMT) Pasien Tuberkulosis Resistan Obat dan Kecenderungannya Terhadap Efek Samping Pengobatan’, Jurnal Teknologi Kesehatan (Journal of Health Technology) [Preprint].
24] Siti Fatimah Az’zahra et al. (2024) ‘Hubungan Antara Usia dan Jenis Kelamin dengan Kejadian Multidrugs-Resistant Tuberculosis (MDR-TB) di Rumah Sakit Paru Dr. M. Goenawan (RSPG) Cisarua Bogor’, Bandung Conference Series: Medical Science, 4(1), pp. 899–905. Available at: https://doi.org/10.29313/bcsms.v4i1.12431.
25] Tadesse, F. (2015) ‘Risk Factors for Multi-drug Resistant Tuberculosis in Addis Ababa, Ethiopia’, Universal Journal of Public Health, 3(2), pp. 65–70. Available at: https://doi.org/10.13189/ujph.2015.030203.
26] Kementerian Kesehatan, R. (2023) Petunjuk Teknis Pemeriksaan Tuberkulosis Menggunakan Tes Cepat Molekuler GeneXpert.
27] Tutuhatunewa, P.R., Hardia, L. and Irwandi (2024) ‘Pengaruh Sosiodemografi terhadap Keberhasilan Pengobatan Pasien TB-RO DI RSUD DR. J. P. WANANE’, Jurnal Kesehatan Tambusai, 5.
28] Wahidah, I. et al. (2024) ‘Determinan pola resistensi pasien Multi-Drug Resistant Tuberculosis (MDRTB) : Studi Multi-Center di Jember, Indonesia’, Indonesian Journal of Pharmaceutical Education (e-Journal), 4(1), pp. 2775–3670. Available at: https://doi.org/10.37311/ijpe.v4i1.24636.
29] Yobeanto, N. and Setiawan, T.L. (2022) ‘Pola Resistensi Kuman Mycobacterium Tuberculosis terhadap Obat Anti Tuberkulosis Lini Pertama’.
30] Zaenab, S., Ronoatmodjo, S. and Putri, M. (2024) ‘Gambaran Diagnosis TBC di Indonesia Tahun 2020-2022’, Jurnal Epidemiologi Kesehatan Indonesia, 8(1). Available at: https://doi.org/10.7454/epidkes.v8i1.1099.
31] Zulfa, N.R.A. and Prihartono, N.A. (2023) ‘Karakteristik Pasien Tuberkulosis di Kota Bandung Tahun 2021’, Jurnal Integrasi Kesehatan & Sains, 5(2), pp. 155–158. Available at: https://doi.org/10.29313/jiks.v5i2.11804.
Downloads
Published
Issue
Section
License
Copyright (c) 2025 Berliana Sitepu
This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.
